Paper Details

  1. Home
  2. Paper Details

A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome.

Author: BardhanK D, BodemarG, GeldofH, HeathA, JacquesL A, MillsJ G, SchützE

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Alosetron, a 5-HT3 receptor antagonist, was found to be effective in treating female patients with irritable bowel syndrome. The 2 mg b.d. dosage significantly increased the proportion of pain-free days and decreased the visual analogue scale score for diarrhea compared to placebo.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Irritable bowel syndrome is a common gastrointestinal disorder characterized by abdominal pain and discomfort and altered bowel habit. Antagonism at the 5-HT3 receptor may be of benefit in the treatment of irritable bowel syndrome. AIMS: To evaluate the effect of 12 weeks of treatment w...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1046/j.1365-2036.2000.00684.x

データ提供：米国国立医学図書館（NLM）

Alosetron: A Potential Treatment for Irritable Bowel Syndrome

This research explores the challenges of irritable bowel syndrome (IBS), a common gastrointestinal disorder characterized by abdominal pain, discomfort, and altered bowel habits, often feeling like a desert storm that disrupts the body's delicate balance. The study investigates the efficacy of alosetron, a 5-HT3 receptor antagonist, like discovering a hidden oasis in a vast desert, offering potential relief from IBS symptoms. The authors meticulously analyze the results of a double-blind, placebo-controlled dose-ranging study, comparing the effects of different doses of alosetron to placebo in patients with IBS.

Alosetron: A Potential Path to IBS Relief

The study reveals that alosetron, at a dose of 2 mg b.d., may be an effective treatment for women with IBS, like discovering a hidden oasis that offers relief from the discomfort and disruption of a desert storm. The authors demonstrate a significant improvement in pain-free days and a reduction in diarrhea in the treatment group compared to placebo. This research suggests that alosetron may be a valuable option for women seeking relief from IBS symptoms.

Navigating IBS: Finding the Right Approach

This research highlights the importance of finding the right treatment approach for IBS, like navigating a desert landscape with multiple paths to consider. The authors emphasize the need for personalized care and a careful consideration of the potential benefits and risks of different therapeutic options. This research also underscores the importance of ongoing research and development of new and improved therapies for IBS, providing a path towards better outcomes for those living with this debilitating condition.

Dr.Camel's Conclusion

This research explores the potential benefits of alosetron, a 5-HT3 receptor antagonist, for the treatment of irritable bowel syndrome, a condition that can feel like navigating a desert storm of discomfort. The study reveals that alosetron may be an effective treatment option for women with IBS, offering a potential path to relief. This research emphasizes the importance of personalized care and a collaborative approach between patients and healthcare providers to find the most effective strategies for managing IBS symptoms.
Date :
  1. Date Completed 2000-02-17
  2. Date Revised 2019-08-31
Further Info :

Pubmed ID

10632642

DOI: Digital Object Identifier

10.1046/j.1365-2036.2000.00684.x

Related Literature

Article Analysis
・Effective treatment of irritable bowel syndrome
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.